Impact of Steatotic Liver Disease Associated With Metabolic Dysfunction (MASLD) on Frailty, Cognition, and Quality of Life. A Gender-sensitive Approach Towards a Comprehensive and Equitable Perspective.

Recruiting now

Conditions studied: Steatosis of Liver

In brief

The goal of this observational study is to determine the differences in the prevalence, characteristics and evolution of frailty between men and women diagnosed with MASLD, and to establish its relationship with clinical, functional, hormonal and social parameters.

Key facts

Study ID

NCT07652892

Run by

Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

People needed

140

Starts

2026-05-26

Expected to finish

2028-05-25

Last updated by the study team

2026-06-17

Who can join

Age: 20 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients will be included who are able to provide informed consent and actively participate in periodic assessments.

You may not qualify if…

• Risky alcohol consumption:
• > 30 g/day in men and > 20 g/day in women. AUDIT score: > 7 points in men, > 5 in women.
• Other liver diseases (viral hepatitis, autoimmune hepatitis, etc.).
• Advanced neurodegenerative diseases or severe psychiatric disorders.
• Severe comorbidities or treatments that, in the researchers' judgment, may affect frailty and quality of life more than metabolic syndrome and liver disease.

Where it is running

• Hospital de la Santa Creu i Sant Pau — Barcelona, Barcelona, Spain (enrolling)
• Hospital de la Santa Creu i Sant Pau — Barcelona, Barcelona, Spain

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.